Lancet Global Health Comment on risks to global pharma supply chain from COVID-19

Author: Marya Lieberman

A comment just published in Lancet Global Health expresses concern for the whole global supply chain due to the COVID-19 pandemic.  M. Lieberman is one of the 53 co-authors.  The comment urges the global community not to loose track of the need to provide access to good quality medical products for all the other illnesses out there.  Already, the epidemic is limiting mass gatherings for medical treatments such as vaccination, creating intense demand for drugs without a good evidence base for use in COVID-19, and curtailing regulatory efforts such as post-market surveillance.